Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Exelixis
Compugen Ltd
Georgetown University
Tempest Therapeutics
Nektar Therapeutics
Incyte Corporation
Celgene